Jeffrey D. Lazar, MD, Ph.D., President and Managing Director, Lazar Associates, LLC
offers almost 40 years of clinical research experience across nearly all aspects of medicine and pharmacology.
Jeff has had several successful careers -- as a bench scientist (he described the first renin inhibitor), a clinical scientist (he was the first to postulate a kinetic effect of estrogens on the renin reaction as a mechanism for the hypertension associated with oral contraceptives), a university professor (he was tenured at the Uniformed Services University - the Department of Defense Medical School), in the pharmaceutical industry (he was the founding director of the Early Clinical Research Group at Pfizer Central Research), and in the CRO industry (he was a senior executive at Pharmaco in Austin, TX, responsible for Toxicology, Phase I, Regulatory Affairs, and Worldwide Consulting Services).
This has provided Jeff
with a unique blend of hands-on experience across all aspects of drug, biologics, and device research.
While at Pfizer, he was the manager responsible for the amlodipine (Norvasc®) NDA and was a senior member of the teams that developed fluconazole (Diflucan®), sertraline (Zoloft®), doxazosin (Cardura®), and azithromycin (Zithromax®/Z-Pac®).
has been involved with multiple NDAs across nearly all therapeutic areas.
Jeff received his MD from the University of Michigan in Ann Arbor and his PhD from The University of Heidelberg (Germany).
trained in Internal Medicine at the University of Michigan
Medical Center, and in Clinical Pharmacology at Vanderbilt University
has over 40 peer-reviewed publications in the